How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Organ and Tissue Transplantation and Alternative Market
- By Organ Type: Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant, Pancreas Transplant, Intestinal Transplant
- By Tissue Type: Corneal Transplant, Skin Grafting, Bone Grafting, Heart Valve Transplant, Cartilage Transplant, Blood Vessel Transplant
- By Transplant Source: Deceased Donor Transplant, Living Donor Transplant, Autograft, Allograft, Xenograft
- By Alternative Treatment Type: Artificial Organs, Bioengineered Organs, Stem Cell Therapy, Immunosuppressive Drugs, Organ Preservation Solutions
- By End-User: Hospitals, Specialized Transplant Centers, Ambulatory Surgical Centers, Research Institutes, Home Care Settings
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Kidney Transplant leads By Organ Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 312 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.188 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.196 →
Full report · locked preview
Everything inside the Organ and Tissue Transplantation and Alternative Market report
A complete, evidence-based study - 12 chapters and 131 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Organ Type 6
Tissue Type 6
Transplant Source 5
Alternative Treatment Type 5
End-User 5
Companies profiled
Organ Recovery Systems
LifeCell Corporation (a subsidiary of Allergan)
RTI Surgical
MiMedx Group Inc.
Osiris Therapeutics Inc.
AxoGen Inc.
Stryker Corporation (Orthobiologics division)
Medtronic (tissue repair and regeneration segment)
AlloSource
Cytograft Tissue Engineering Inc.
TransMedics Inc.
CryoLife Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Organ Recovery Systems
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →LifeCell Corporation (a subsidiary of Allergan)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →RTI Surgical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →MiMedx Group Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Osiris Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →AxoGen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Stryker Corporation (Orthobiologics division)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Medtronic (tissue repair and regeneration segment)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →AlloSource
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Cytograft Tissue Engineering Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →TransMedics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →CryoLife Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Vericel Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Organovo Holdings Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →BioLife Solutions
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,541M by 2033 · 6.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Kidney Transplant27.8
- Liver Transplant9.1
- Heart Transplant19.0
- Lung Transplant16.6
- Pancreas Transplant11.6
- Intestinal Transplant15.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,457M → $2,664M · 7.8%
Europe$1,016M → $1,858M · 7.8%
Asia Pacific$927.4M → $1,628M · 7.3%
Latin America$574.1M → $927.2M · 6.2%
Middle East and Africa$441.6M → $835.4M · 8.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.872026
6.882027
6.892028
6.902029
6.912030
6.942031
6.942032
6.952033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Organ Recovery Systems20.8
- LifeCell Corporation (a subsidiary of Allergan)17.1
- RTI Surgical7.0
- MiMedx Group Inc.5.2
- Osiris Therapeutics Inc.14.0
- AxoGen Inc.7.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Organ Type31.4%
Tissue Type27.8%
Transplant Source20.2%
Alternative Treatment Type10.7%
End-User9.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.7
- Europe23.5
- Asia Pacific20.6
- Latin America11.7
- Middle East and Africa10.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Organ Recovery Systems | 91 | 82 | 91 | 84 | 92 | 84 | 87 |
| LifeCell Corporation (a subsidiary of Allergan) | 78 | 72 | 83 | 74 | 86 | 86 | 80 |
| RTI Surgical | 75 | 73 | 65 | 78 | 69 | 65 | 71 |
| MiMedx Group Inc. | 70 | 68 | 67 | 60 | 72 | 69 | 68 |
| Osiris Therapeutics Inc. | 63 | 69 | 62 | 65 | 54 | 66 | 63 |
| AxoGen Inc. | 66 | 53 | 52 | 46 | 65 | 58 | 57 |
| Stryker Corporation (Orthobiologics division) | 42 | 61 | 56 | 49 | 61 | 59 | 55 |
| Medtronic (tissue repair and regeneration segment) | 36 | 35 | 59 | 51 | 42 | 37 | 43 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Organ Recovery Systems
- LifeCell Corporation (a subsidiary of Allergan)
- RTI Surgical
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Organ Recovery Systems | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| LifeCell Corporation (a subsidiary of Allergan) | ◐ | ✓ | ✓ | ◐ | ✓ | ✓ |
| RTI Surgical | ✓ | ◐ | ◐ | ✓ | ◐ | − |
| MiMedx Group Inc. | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Osiris Therapeutics Inc. | − | − | ◐ | ◐ | ◐ | ◐ |
| AxoGen Inc. | ◐ | − | − | ◐ | ◐ | ◐ |
| Stryker Corporation (Orthobiologics division) | ◐ | ◐ | − | − | ◐ | ◐ |
| Medtronic (tissue repair and regeneration segment) | ◐ | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Organ Recovery Systems87
2LifeCell Corporation (a subsidiary of Allergan)80
3RTI Surgical71
4MiMedx Group Inc.68
5Osiris Therapeutics Inc.63
6AxoGen Inc.57
7Stryker Corporation (Orthobiologics division)55
8Medtronic (tissue repair and regeneration segment)43
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Organ Recovery SystemsLifeCell Corporation (a subsidiary of Allergan)
Challenger2
Strong scale, closing on the leaders.
RTI SurgicalMiMedx Group Inc.
Contender2
Focused players with pockets of strength.
Osiris Therapeutics Inc.AxoGen Inc.
Niche2
Specialists in a single segment or region.
Stryker Corporation (Orthobiologics division)Medtronic (tissue repair and regeneration segment)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Organ Type in North America, then scale across Organ and Tissue Transplantation and Alternative Market — a $305M beachhead inside a $5.74B market.
Beachhead (SOM)$305Mobtainable near-term
Serviceable (SAM)$1.96Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Kidney Transplant
Best fit — highest urgency & budget in Organ Type.
Economic buyer78 fit
Liver Transplant
Strong fit — clear ROI and a fast path to value.
End user70 fit
Heart Transplant
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Organ Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Tissue Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Transplant Source
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel30%
Digital / self-serve20%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Organ Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Organ and Tissue Transplantation and Alternative Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified24%
Evaluation15%
Closed-won6%
$17.2KCAC
$98KLTV
5.7:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Organ and Tissue Transplantation and Alternative Market is a high-growth opportunity — $4.72B by 2033, compounding at 10.3%.
TAM · 2025$2.15Btoday
TAM · 2033$4.72Bforecast
CAGR10.3%2027–2033
Cumulative$29.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.72BTotal addressable market
SAM$1.94BServiceable available market
SOM$357MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.3% CAGR
Demand compounds through 2033, outpacing GDP across Organ Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Organ Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.72BLarge & growingTAM by 2033 at 10.3% CAGR
$1.94BServiceable nowreachable with today’s model
$357MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.68BBear6.7% CAGR
$4.72BBase10.3% CAGR
$6.04BBull13.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Tissue Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Organ and Tissue Transplantation and Alternative Market — a $9.29B market by 2033. Plan: grow share from 5.6% to 12.2%.
Market size · 2033$9.29Btotal addressable
Market CAGR9.6%2027–2033
Target share12.2%from 5.6% today
Revenue ambition$1.13Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.6% | 12.2% | On track |
| Revenue | $485M | $1.13B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 35.3% | 43.8% | At risk |
| Customer retention | 85.6% | 93.2% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Organ Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Tissue Type capability
A defensible second engine — invest in Tissue Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Organ Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Tissue Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $164M capacity & capability investment
- Greenlight bolt-on M&A in Tissue Type
- Authorise North America expansion plan
- Fund R&D program for Organ Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Organ and Tissue Transplantation and Alternative Market conversation — a $4.17B market you can size, segment and defend in minutes.
Market size · 2033$4.17Btotal opportunity
Growth5.2%CAGR to 2033
Addressable buyers1,313+accounts in scope
Typical ROI5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Organ Type
Goal Grow share in Organ Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5×return on cost, year one
< 4 mopayback period
$80K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Organ Recovery SystemsLifeCell Corporation (a subsidiary of Allergan)RTI SurgicalMiMedx Group Inc.Osiris Therapeutics Inc.AxoGen Inc.Stryker Corporation (Orthobiologics division)Medtronic (tissue repair and regeneration segment)+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Organ and Tissue Transplantation and Alternative Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Organ and Tissue Transplantation and Alternative Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Orexin Receptor Antagonists Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportOrexin Receptor Antagonists for Insomnia Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportOrelabrutinib Tablets Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportOrbital Tissue Expander Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportOrbital Shaking Incubator Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportOrbital Shaker Incubator Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportOrbitally Shaken Bioreactors Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportOrbital Laboratory Shakers Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportOrbital Atherectomy Device Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportOral X-Ray Imaging System Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportOral X-ray Films Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportOral Wound Dressing Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.